Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAvMh603Ea9WcuNUL1l9ZWlSlfYZwoQZ6GC-hfo7YpLWc#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- association type Statement assertion.
- context type Cohort assertion.
- MONDO_0005689 type Disease assertion.
- DRUGBANK:DB01175 type Drug assertion.
- association label "Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature." assertion.
- context label "Adults" assertion.
- association object MONDO_0005689 assertion.
- association predicate treats assertion.
- association subject DRUGBANK:DB01175 assertion.
- association relation OffLabelIndication assertion.
- association publications 32227801 assertion.
- association provided_by NeuroDKG assertion.
- association has_population_context context assertion.